A phase ii trial of cetuximab, gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma

Volkan Cetin, Bilal Piperdi, Venu Bathini, William V. Walsh, Shakeeb Yunus, Jennifer F. Tseng, Giles F. Whalen, Wahid Y. Wassef, Sidney P. Kadish, Thomas J. Fitzgerald, Christine Mikule, Yuxia Wang, Steven R. Grossman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. A minority of patients present with localized disease and surgical resection still offers patients the only hope for long-term survival. Locally advanced pancreatic cancer is defined as surgically unresectable, but has no evidence of distant metastases. The purpose of this study is to evaluate the efficacy and safety of cetuximab in combination with gemcitabine and 5-FU along with radiation therapy in locally advanced non-resectable, pancreatic adenocarci-noma, using progression free survival as the primary end point. METHODS: This was a prospective, single arm, open label pilot phase II study to evaluate the anti-tumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (250 mg/m2 per week after an initial 400 mg/m2 loading dose) with continuous infusion 5-FU (800 mg/m2 over 96 hours) and daily concurrent external beam radiation therapy (50.4 Gy total dose) for six weeks (cycle 1) in patients with non-metastatic, locally advanced pancreatic adenocarcinoma. Following neoad-juvant treatment, subjects were re-evaluated for response and surgical candidacy with restaging scans. After resection, or also if not resected; subjects received further therapy with four 28-day cycles (cycles 2-5) of weekly gemcitabine (1000 mg/m2) and cetuximab (250 mg/m2) on days 1, 8, and 15. RESULTS: Between 2006 and 2011, twenty-six patients were screened and eleven of them were enrolled in the study. Most common reasons for screen failures were having resectable disease, metastatic disease or co-morbidity. Ten patients were able to tolerate and complete cycle 1 of chemoradiotherapy. One patient stopped the study prematurely due to grade III diarrhea. All except this one patient received planned radiation therapy. The response evaluation after cycle 1 showed one Partial Response, eight Stable Disease and two Progressive Disease. Four patients subsequently underwent surgical resection of the tumor. All patients had R0 resections. There was one preoperative mortality due to multiple organ failure. Median progression free survival (PFS) for four resected patients was 9.0 months while for unresected patients median PFS was 7.1 months. Median overall survival (OS) for four resected patients was 47.4 months and for unresected patients median OS was 17.0 months. Most common adverse events were hematologic (27%). Only two patients developed grade 3 neutropenia. Most common treatment related non-hematologic adverse events were diarrhea (10 of 11), nausea (8 of 11) and skin rash (10 of 11 patients). Only 9.5% of all reported non-hematologic adverse events were grade 3 or higher. CONCLUSIONS: The combination of cetuximab, weekly gemcitabine and continuous infusion of 5-FU with radiotherapy was quite well tolerated with intriguing clinical benefit and survival results in carefully selected patients with locally advanced pancreatic adenocarcinoma. A trial with larger sample size will be necessary to confirm these results.

Original languageEnglish (US)
Pages (from-to)2-9
Number of pages8
JournalGastrointestinal Cancer Research
Volume6
Issue number4 SUPPL.1
StatePublished - 2013

Fingerprint

gemcitabine
Fluorouracil
Adenocarcinoma
Radiotherapy
Disease-Free Survival
Survival
Cetuximab
Pancreatic Neoplasms
Diarrhea

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

A phase ii trial of cetuximab, gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma. / Cetin, Volkan; Piperdi, Bilal; Bathini, Venu; Walsh, William V.; Yunus, Shakeeb; Tseng, Jennifer F.; Whalen, Giles F.; Wassef, Wahid Y.; Kadish, Sidney P.; Fitzgerald, Thomas J.; Mikule, Christine; Wang, Yuxia; Grossman, Steven R.

In: Gastrointestinal Cancer Research, Vol. 6, No. 4 SUPPL.1, 2013, p. 2-9.

Research output: Contribution to journalArticle

Cetin, V, Piperdi, B, Bathini, V, Walsh, WV, Yunus, S, Tseng, JF, Whalen, GF, Wassef, WY, Kadish, SP, Fitzgerald, TJ, Mikule, C, Wang, Y & Grossman, SR 2013, 'A phase ii trial of cetuximab, gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma', Gastrointestinal Cancer Research, vol. 6, no. 4 SUPPL.1, pp. 2-9.
Cetin, Volkan ; Piperdi, Bilal ; Bathini, Venu ; Walsh, William V. ; Yunus, Shakeeb ; Tseng, Jennifer F. ; Whalen, Giles F. ; Wassef, Wahid Y. ; Kadish, Sidney P. ; Fitzgerald, Thomas J. ; Mikule, Christine ; Wang, Yuxia ; Grossman, Steven R. / A phase ii trial of cetuximab, gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma. In: Gastrointestinal Cancer Research. 2013 ; Vol. 6, No. 4 SUPPL.1. pp. 2-9.
@article{2e7dee462cc9451989727d5484d9f07c,
title = "A phase ii trial of cetuximab, gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma",
abstract = "BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. A minority of patients present with localized disease and surgical resection still offers patients the only hope for long-term survival. Locally advanced pancreatic cancer is defined as surgically unresectable, but has no evidence of distant metastases. The purpose of this study is to evaluate the efficacy and safety of cetuximab in combination with gemcitabine and 5-FU along with radiation therapy in locally advanced non-resectable, pancreatic adenocarci-noma, using progression free survival as the primary end point. METHODS: This was a prospective, single arm, open label pilot phase II study to evaluate the anti-tumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (250 mg/m2 per week after an initial 400 mg/m2 loading dose) with continuous infusion 5-FU (800 mg/m2 over 96 hours) and daily concurrent external beam radiation therapy (50.4 Gy total dose) for six weeks (cycle 1) in patients with non-metastatic, locally advanced pancreatic adenocarcinoma. Following neoad-juvant treatment, subjects were re-evaluated for response and surgical candidacy with restaging scans. After resection, or also if not resected; subjects received further therapy with four 28-day cycles (cycles 2-5) of weekly gemcitabine (1000 mg/m2) and cetuximab (250 mg/m2) on days 1, 8, and 15. RESULTS: Between 2006 and 2011, twenty-six patients were screened and eleven of them were enrolled in the study. Most common reasons for screen failures were having resectable disease, metastatic disease or co-morbidity. Ten patients were able to tolerate and complete cycle 1 of chemoradiotherapy. One patient stopped the study prematurely due to grade III diarrhea. All except this one patient received planned radiation therapy. The response evaluation after cycle 1 showed one Partial Response, eight Stable Disease and two Progressive Disease. Four patients subsequently underwent surgical resection of the tumor. All patients had R0 resections. There was one preoperative mortality due to multiple organ failure. Median progression free survival (PFS) for four resected patients was 9.0 months while for unresected patients median PFS was 7.1 months. Median overall survival (OS) for four resected patients was 47.4 months and for unresected patients median OS was 17.0 months. Most common adverse events were hematologic (27{\%}). Only two patients developed grade 3 neutropenia. Most common treatment related non-hematologic adverse events were diarrhea (10 of 11), nausea (8 of 11) and skin rash (10 of 11 patients). Only 9.5{\%} of all reported non-hematologic adverse events were grade 3 or higher. CONCLUSIONS: The combination of cetuximab, weekly gemcitabine and continuous infusion of 5-FU with radiotherapy was quite well tolerated with intriguing clinical benefit and survival results in carefully selected patients with locally advanced pancreatic adenocarcinoma. A trial with larger sample size will be necessary to confirm these results.",
author = "Volkan Cetin and Bilal Piperdi and Venu Bathini and Walsh, {William V.} and Shakeeb Yunus and Tseng, {Jennifer F.} and Whalen, {Giles F.} and Wassef, {Wahid Y.} and Kadish, {Sidney P.} and Fitzgerald, {Thomas J.} and Christine Mikule and Yuxia Wang and Grossman, {Steven R.}",
year = "2013",
language = "English (US)",
volume = "6",
pages = "2--9",
journal = "Gastrointestinal Cancer Research",
issn = "1934-7820",
publisher = "International Society of Gastrointestinal Oncology",
number = "4 SUPPL.1",

}

TY - JOUR

T1 - A phase ii trial of cetuximab, gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma

AU - Cetin, Volkan

AU - Piperdi, Bilal

AU - Bathini, Venu

AU - Walsh, William V.

AU - Yunus, Shakeeb

AU - Tseng, Jennifer F.

AU - Whalen, Giles F.

AU - Wassef, Wahid Y.

AU - Kadish, Sidney P.

AU - Fitzgerald, Thomas J.

AU - Mikule, Christine

AU - Wang, Yuxia

AU - Grossman, Steven R.

PY - 2013

Y1 - 2013

N2 - BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. A minority of patients present with localized disease and surgical resection still offers patients the only hope for long-term survival. Locally advanced pancreatic cancer is defined as surgically unresectable, but has no evidence of distant metastases. The purpose of this study is to evaluate the efficacy and safety of cetuximab in combination with gemcitabine and 5-FU along with radiation therapy in locally advanced non-resectable, pancreatic adenocarci-noma, using progression free survival as the primary end point. METHODS: This was a prospective, single arm, open label pilot phase II study to evaluate the anti-tumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (250 mg/m2 per week after an initial 400 mg/m2 loading dose) with continuous infusion 5-FU (800 mg/m2 over 96 hours) and daily concurrent external beam radiation therapy (50.4 Gy total dose) for six weeks (cycle 1) in patients with non-metastatic, locally advanced pancreatic adenocarcinoma. Following neoad-juvant treatment, subjects were re-evaluated for response and surgical candidacy with restaging scans. After resection, or also if not resected; subjects received further therapy with four 28-day cycles (cycles 2-5) of weekly gemcitabine (1000 mg/m2) and cetuximab (250 mg/m2) on days 1, 8, and 15. RESULTS: Between 2006 and 2011, twenty-six patients were screened and eleven of them were enrolled in the study. Most common reasons for screen failures were having resectable disease, metastatic disease or co-morbidity. Ten patients were able to tolerate and complete cycle 1 of chemoradiotherapy. One patient stopped the study prematurely due to grade III diarrhea. All except this one patient received planned radiation therapy. The response evaluation after cycle 1 showed one Partial Response, eight Stable Disease and two Progressive Disease. Four patients subsequently underwent surgical resection of the tumor. All patients had R0 resections. There was one preoperative mortality due to multiple organ failure. Median progression free survival (PFS) for four resected patients was 9.0 months while for unresected patients median PFS was 7.1 months. Median overall survival (OS) for four resected patients was 47.4 months and for unresected patients median OS was 17.0 months. Most common adverse events were hematologic (27%). Only two patients developed grade 3 neutropenia. Most common treatment related non-hematologic adverse events were diarrhea (10 of 11), nausea (8 of 11) and skin rash (10 of 11 patients). Only 9.5% of all reported non-hematologic adverse events were grade 3 or higher. CONCLUSIONS: The combination of cetuximab, weekly gemcitabine and continuous infusion of 5-FU with radiotherapy was quite well tolerated with intriguing clinical benefit and survival results in carefully selected patients with locally advanced pancreatic adenocarcinoma. A trial with larger sample size will be necessary to confirm these results.

AB - BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. A minority of patients present with localized disease and surgical resection still offers patients the only hope for long-term survival. Locally advanced pancreatic cancer is defined as surgically unresectable, but has no evidence of distant metastases. The purpose of this study is to evaluate the efficacy and safety of cetuximab in combination with gemcitabine and 5-FU along with radiation therapy in locally advanced non-resectable, pancreatic adenocarci-noma, using progression free survival as the primary end point. METHODS: This was a prospective, single arm, open label pilot phase II study to evaluate the anti-tumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (250 mg/m2 per week after an initial 400 mg/m2 loading dose) with continuous infusion 5-FU (800 mg/m2 over 96 hours) and daily concurrent external beam radiation therapy (50.4 Gy total dose) for six weeks (cycle 1) in patients with non-metastatic, locally advanced pancreatic adenocarcinoma. Following neoad-juvant treatment, subjects were re-evaluated for response and surgical candidacy with restaging scans. After resection, or also if not resected; subjects received further therapy with four 28-day cycles (cycles 2-5) of weekly gemcitabine (1000 mg/m2) and cetuximab (250 mg/m2) on days 1, 8, and 15. RESULTS: Between 2006 and 2011, twenty-six patients were screened and eleven of them were enrolled in the study. Most common reasons for screen failures were having resectable disease, metastatic disease or co-morbidity. Ten patients were able to tolerate and complete cycle 1 of chemoradiotherapy. One patient stopped the study prematurely due to grade III diarrhea. All except this one patient received planned radiation therapy. The response evaluation after cycle 1 showed one Partial Response, eight Stable Disease and two Progressive Disease. Four patients subsequently underwent surgical resection of the tumor. All patients had R0 resections. There was one preoperative mortality due to multiple organ failure. Median progression free survival (PFS) for four resected patients was 9.0 months while for unresected patients median PFS was 7.1 months. Median overall survival (OS) for four resected patients was 47.4 months and for unresected patients median OS was 17.0 months. Most common adverse events were hematologic (27%). Only two patients developed grade 3 neutropenia. Most common treatment related non-hematologic adverse events were diarrhea (10 of 11), nausea (8 of 11) and skin rash (10 of 11 patients). Only 9.5% of all reported non-hematologic adverse events were grade 3 or higher. CONCLUSIONS: The combination of cetuximab, weekly gemcitabine and continuous infusion of 5-FU with radiotherapy was quite well tolerated with intriguing clinical benefit and survival results in carefully selected patients with locally advanced pancreatic adenocarcinoma. A trial with larger sample size will be necessary to confirm these results.

UR - http://www.scopus.com/inward/record.url?scp=84891641622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891641622&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 2

EP - 9

JO - Gastrointestinal Cancer Research

JF - Gastrointestinal Cancer Research

SN - 1934-7820

IS - 4 SUPPL.1

ER -